MRD test guides PD-1 treatment after liver cancer surgery
Part of Cancer clinical trials.
This trial uses a blood test called minimal residual disease (MRD) to predict if liver cancer will come back after surgery or ablation. It also tests if adding an immunotherapy drug (PD-1 inhibitor) can help prevent recurrence in high-risk patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been newly diagnosed with liver cancer that hasn't been treated yet.
- You must have had surgery or microwave ablation to remove your tumors.
- You must have at least one high-risk feature, like tumor invasion into blood vessels, poor cell differentiation, more than one tumor, or a tumor larger than 5 cm.
- Your liver function must be fair (Child-Pugh score 7 or less).
- You should be in good general health (able to do daily activities with little help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial tests whether giving an immunotherapy drug (anti-PD-1) after surgery can help prevent liver cancer from coming back. It is for people who have had their liver tumor completely removed and have good enough liver function.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study tests if a blood test for 'minimal residual disease' (tiny bits of cancer left after treatment) can help predict how well therapy works for prostate cancer that has spread and is sensitive to hormones. It aims to find better ways to guide treatment and monitor the cancer.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Hear when a new Minimal Residual Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.